FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2968996929> ?p ?o ?g. }

• W2968996929 abstract "SY27-02 We have designed a loss-of-function screen for genes required for the proliferation and survival of cancer cells using an RNA interference library. We are using this “Achilles heel” screen to identify those cellular proteins and pathways that are most vulnerable to therapeutic attack. A doxycycline-inducible retroviral vector for the expression of small hairpin RNAs (shRNAs) was used to construct a library targeting 2,500 human genes, with each gene targeting by 3-6 shRNAs. Each vector was engineered to contain a unique 60-base pair “bar code”, allowing the abundance of an individual shRNA vector within a population of transduced cells to be measured using microarrays of the bar code sequences. In a typical screen, retroviral pools of 500-1000 vectors from this library are used to a infect cancer cell line. After selection for stable integration, doxycycline is added to half of the culture to induce shRNA expression, and the remaining half serves as an uninduced control. These two cultures are then grown in parallel for 3 weeks, during which time cells expressing toxic shRNAs will be depleted from the induced culture. DNA bar code microarrays are used to compare the abundance of each shRNA vector in the induced versus uninduced populations, thereby revealing which shRNAs inhibited the proliferation or survival of the cancer cells. In our genetic screens, we have use a “synthetic lethal” strategy in which we search for shRNAs that are only toxic to cancer types with particular underlying genetic lesions. To this end, we conducted parallel screens in two distinct molecular subgroups of diffuse large B cell lymphoma (DLBCL) termed activated B cell-like (ABC) DLBCL and germinal center B cell-like (GCB) DLBCL. These two subgroups are profoundly different in their pathogenesis in that they arise from different stages of normal B lymphocyte development and utilize distinct oncogenic mechanims. Notably, we had previously discovered that the ABC DLBCL subgroup depends upon the NF-kB pathway for survival, but the GCB DLBCL subgroup does not. However, we did not know which upstream signaling pathways in ABC DLBCLs were responsible for their constitutive activaty of the IkB kinase, the key regulator of the NF-kB pathway. Remarkably, shRNAs targeting the NF-kB pathway were depleted in screens of ABC DLBCL but not GCB DLBCL cells, in keeping with the essential role of this pathway in the survival of ABC DLBCL. Unexpectedly, this screen uncovered an upstream signaling pathway involving CARD11, MALT1 and BCL10 that is responsible for the constitutive NF-kB activity in ABC DLBCL. Knock down of any of these genes with shRNAs descreased IkB kinase activity, NF-kB target gene expression, and cell viability. The CARD11 pathway therefore represents an attractive new therapeutic target for the ABC DLBCL subgroup. Importantly, therapeutic targeting of this pathway is likely to have discrete and manageable toxicity since mice that are deficient in these genes are viable and only have defects in subsets of B and T lymphocytes. More recently, we have used the Achilles heel methodology to discover genes essential for cellular proliferation and survival in other forms of lymphoid malignancy. We believe that a new taxonomy of cancer may emerge in which cancers are defined by their critical dependence on particular signaling pathways for survival and proliferation. Another important use of this technology will be to evaluate which of the many somatically mutated genes in human cancer make the most important ongoing contributions to the biology of cancer cells. Finally, these genetic screens are revealing that cancers may “inherit” from their normal cellular counterparts a dependance on particular regulatory pathways for their proliferation and survival. These pathways may not necessary be affected by genetic alterations but the cancer cells may nevertheless be “addicted” to their continous activity. Therefore, this methodology has the potential to uncover a new class of therapeutic targets distinct from known oncogenes." @default.
• W2968996929 created "2019-08-22" @default.
• W2968996929 creator A5025942951 @default.
• W2968996929 date "2007-05-01" @default.
• W2968996929 modified "2023-09-23" @default.
• W2968996929 title "Loss of function RNA interference screens for molecular targets in cancer" @default.
• W2968996929 hasPublicationYear "2007" @default.
• W2968996929 type Work @default.
• W2968996929 sameAs 2968996929 @default.
• W2968996929 citedByCount "0" @default.
• W2968996929 crossrefType "journal-article" @default.
• W2968996929 hasAuthorship W2968996929A5025942951 @default.
• W2968996929 hasConcept C104317684 @default.
• W2968996929 hasConcept C121608353 @default.
• W2968996929 hasConcept C150194340 @default.
• W2968996929 hasConcept C166703698 @default.
• W2968996929 hasConcept C190232843 @default.
• W2968996929 hasConcept C2908647359 @default.
• W2968996929 hasConcept C32470452 @default.
• W2968996929 hasConcept C40767141 @default.
• W2968996929 hasConcept C502942594 @default.
• W2968996929 hasConcept C54355233 @default.
• W2968996929 hasConcept C67705224 @default.
• W2968996929 hasConcept C70721500 @default.
• W2968996929 hasConcept C71924100 @default.
• W2968996929 hasConcept C86803240 @default.
• W2968996929 hasConcept C92087593 @default.
• W2968996929 hasConcept C95371953 @default.
• W2968996929 hasConcept C99454951 @default.
• W2968996929 hasConceptScore W2968996929C104317684 @default.
• W2968996929 hasConceptScore W2968996929C121608353 @default.
• W2968996929 hasConceptScore W2968996929C150194340 @default.
• W2968996929 hasConceptScore W2968996929C166703698 @default.
• W2968996929 hasConceptScore W2968996929C190232843 @default.
• W2968996929 hasConceptScore W2968996929C2908647359 @default.
• W2968996929 hasConceptScore W2968996929C32470452 @default.
• W2968996929 hasConceptScore W2968996929C40767141 @default.
• W2968996929 hasConceptScore W2968996929C502942594 @default.
• W2968996929 hasConceptScore W2968996929C54355233 @default.
• W2968996929 hasConceptScore W2968996929C67705224 @default.
• W2968996929 hasConceptScore W2968996929C70721500 @default.
• W2968996929 hasConceptScore W2968996929C71924100 @default.
• W2968996929 hasConceptScore W2968996929C86803240 @default.
• W2968996929 hasConceptScore W2968996929C92087593 @default.
• W2968996929 hasConceptScore W2968996929C95371953 @default.
• W2968996929 hasConceptScore W2968996929C99454951 @default.
• W2968996929 hasLocation W29689969291 @default.
• W2968996929 hasOpenAccess W2968996929 @default.
• W2968996929 hasPrimaryLocation W29689969291 @default.
• W2968996929 hasRelatedWork W1607425105 @default.
• W2968996929 hasRelatedWork W1864462827 @default.
• W2968996929 hasRelatedWork W1967001037 @default.
• W2968996929 hasRelatedWork W1971617980 @default.
• W2968996929 hasRelatedWork W2013689460 @default.
• W2968996929 hasRelatedWork W2073050084 @default.
• W2968996929 hasRelatedWork W2075077797 @default.
• W2968996929 hasRelatedWork W2106300717 @default.
• W2968996929 hasRelatedWork W2114918622 @default.
• W2968996929 hasRelatedWork W2131611002 @default.
• W2968996929 hasRelatedWork W2259246578 @default.
• W2968996929 hasRelatedWork W2410569012 @default.
• W2968996929 hasRelatedWork W2474909380 @default.
• W2968996929 hasRelatedWork W2492306406 @default.
• W2968996929 hasRelatedWork W2751134696 @default.
• W2968996929 hasRelatedWork W2755588714 @default.
• W2968996929 hasRelatedWork W2980264254 @default.
• W2968996929 hasRelatedWork W69332521 @default.
• W2968996929 hasRelatedWork W2906518416 @default.
• W2968996929 hasVolume "67" @default.
• W2968996929 isParatext "false" @default.
• W2968996929 isRetracted "false" @default.
• W2968996929 magId "2968996929" @default.
• W2968996929 workType "article" @default.